The purpose of this study was to determine whether a preparation of controlled-release alpha lipoic acid (CRLA) Influences features of the polycystic ovary syndrome (PCOS).
Methods:
We administered CRLA 600 mg twice daily for 16 weeks to six lean, nondiabetic patients with PCOS. Insulin sensitivity was measured by the euglycemic, hyperinsulinemic clamp. Plasma lipids were measured by vertical ultracentrifugation. Oxidative stress markers were measured in serum.
Results:
At the end of 16 weeks of CRLA treatment, there was a 13.5% improvement in insulin sensitivity as determined by the euglycemic, hyperinsulinemic clamp (p < .03). There was also a lowering of triglyceride levels (p < .04) and a shift in the distribution of low-density lipoprotein (LDL) particles toward the larger, more buoyant LDL subclass fraction. Two of the subjects who were not on oral contraception had an increased number of menstrual cycles. Controlled-release alpha lipoic acid treatment, however, was neither associated with an increase in plasma antioxidant capacity nor with a reduction in plasma lipid oxidation products.
Conclusions:
These data suggest that the CRLA has positive effects on the PCOS phenotype. The effects of CRLA, however, may have been exerted through a mechanism not involving changes in oxidative stress.
KnochenhauerESKeyTJKahsar-MillerMWaggonerWBootsLRAzzizR. Prevalence of the polycystic ovary syndrome in unselected black and white women of the southeastern United States: a prospective study. J Clin Endocrinol Metab.1998;83 (9): 3078–82.
2.
EhrmannDA. Polycystic ovary syndrome. N Engl J Med.2005;352 (12): 1223–36.
3.
ChangRJNakamuraRMJuddHLKaplanSA. Insulin resistance in nonobese patients with polycystic ovarian disease. J Clin Endocrinol Metab.1983;57 (2): 356–9.
4.
HolteJBerghTBerneCLithellH. Serum lipoprotein lipid profile in women with the polycystic ovary syndrome: relation to anthropometric, endocrine and metabolic variables. Clin Endocrinol (Oxf).1994;41 (4): 463–71.
5.
MoralesAJLaughlinGABützowTMaheshwariHBaumannGYenSS. Insulin, somatotropic, and luteinizing hormone axes in lean and obese women with polycystic ovary syndrome: common and distinct features. J Clin Endocrinol Metab.1996;81 (8): 2854–64.
6.
Morin-PapunenLCVauhkonenIKoivunenRMRuokonenATapanainenJS. Insulin sensitivity, insulin secretion, and metabolic and hormonal parameters in healthy women and women with polycystic ovarian syndrome. Hum Reprod.2000;15 (6): 1266–74.
7.
OvesenPMollerJIngerslevHJJørgensenJOMengelASchmitzOAlbertiKGMollerN. Normal basal and insulin-stimulated fuel metabolism in lean women with the polycystic ovary syndrome. J Clin Endocrinol Metab.1993;77 (6): 1636–40.
8.
MoghettiPCastelloRNegriCTosiFPerroneFCaputoMZanolinEMuggeoM. Metformin effects on clinical features, endocrine and metabolic profiles, and insulin sensitivity in polycystic ovary syndrome: a randomized, double-blind, placebo-controlled 6-month trial, followed by open, long-term clinical evaluation. J Clin Endocrinol Metab.2000;85 (1): 139–46.
9.
RautioKTapanainenJSRuokonenAMorin-PapunenLC. Endocrine and metabolic effects of rosiglitazone in overweight women with PCOS: a randomized placebo-controlled study. Hum Reprod.2006;21 (6): 1400–7.
10.
GoldenbergNGlueckC. Medical therapy in women with polycystic ovarian syndrome before and during pregnancy and lactation. Minerva Ginecol.2008;60 (1): 63–75.
11.
EvansJLGoldfineIDMadduxBAGrodskyGM. Are oxidative stress-activated signaling pathways mediators of insulin resistance and beta-cell dysfunction?Diabetes.2003;52 (1): 1–8.
12.
FenkciVFenkciSYilmazerMSerteserM. Decreased total antioxidant status and increased oxidative stress in women with polycystic ovary syndrome may contribute to the risk of cardiovascular disease. Fertil Steril.2003;80 (1): 123–7.
13.
GopalakrishnaRJakenS. Protein kinase C signaling and oxidative stress. Free Radic Biol Med.2000;28 (9): 1349–61.
14.
PolakGKoziol-MontewkaMTarkowskiRKotarskiJ. [Peritoneal fluid and plasma 4-hydroxynonenal and malonyldialdehyde concentrations in infertile women]. Ginekol Pol.2001;72 (12A): 1316–20.
15.
SabuncuTVuralHHarmaMHarmaM. Oxidative stress in polycystic ovary syndrome and its contribution to the risk of cardiovascular disease. Clin Biochem.2001;34 (5): 407–13.
16.
EvansJLHeymannCJGoldfineIDGavinLA. Pharmacokinetics, tolerability, and fructosamine-lowering effect of a novel, controlled-release formulation of alpha-lipoic acid. Endocr Pract.2002;8 (1): 29–35.
17.
Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertil Steril.2004;81 (1): 19–25.
18.
FerrimanDGallweyJD. Clinical assessment of body hair growth in women. J Clin Endocrinol Metab.1961;21: 1440–7.
19.
DeFronzoRATobinJDAndresR. Glucose clamp technique: a method for quantifying insulin secretion and resistance. Am J Physiol.1979;237 (3): E214–23.
20.
KulkarniKRGarberDWJonesMKSegrestJ P.identification and cholesterol quantification of low density lipoprotein subclasses in young adults by VAP-II methodology. J Lipid Res.1995;36 (11): 2291–302.
21.
SharmaSTNestlerJE. Prevention of diabetes and cardiovascular disease in women with PCOS: treatment with insulin sensitizers. Best Pract Res Clin Endocrinol Metab.2006;20 (2): 245–60.
22.
CibulaD. Is insulin resistance an essential component of PCOS?: The Influence of confounding factors. Hum Reprod.2004;19 (4): 757–9.
23.
DeUgarteCMBartolucciAAAzzizR. Prevalence of insulin resistance in the polycystic ovary syndrome using the homeostasis model assessment. Fertil Steril.2005;83 (5): 1454–60.
24.
HolteJBerghTBerneCWideLLithellH. Restored insulin sensitivity but persistently increased early insulin secretion after weight loss in obese women with polycystic ovary syndrome. J Clin Endocrinol Metab.1995;80 (9): 2586–93.
25.
BaillargeonJPJakubowiczDJIuornoMJJakubowiczSNestlerJE. Effects of metformin and rosiglitazone, alone and in combination, in nonobese women with polycystic ovary syndrome and normal indices of insulin sensitivity. Fertil Steril.2004;82 (4): 893–902.
26.
ReavenGM. Banting lecture 1988. Role of insulin resistance in human disease. Diabetes.1988;37 (12): 1595–607.
27.
WangJFSchrammDDHoltRREnsunsaJLFragaCGSchmitzHHKeenCL. A dose-response effect from chocolate consumption on plasma epicatechin and oxidative damage. J Nutr.2000;130 (8S Suppl): 2115S–9S.
28.
HutchinsonDSSummersRJBengtssonT. Regulation of AMP-activated protein kinase activity by G-protein coupled receptors: potential utility in treatment of diabetes and heart disease. Pharmacol Ther.2008;119 (3): 291–310.
29.
ViolletBMounierRLeclercJYazigiAForetzMAndreelliF. Targeting AMP-activated protein kinase as a novel therapeutic approach for the treatment of metabolic disorders. Diabetes Metab.2007;33 (6): 395–402.
30.
ZhouGMyersRLiYChenYShenXFenyk-MelodyJWuMVentreJDoebberTFujiiNMusiNHirshmanMFGoodyearLJMollerDE. Role of AMP-activated protein kinase in mechanism of metformin action. J Clin Invest.2001;108 (8): 1167–74.
31.
LeeWJSongKHKohEHWonJCKimHSParkHSKimMSKimSWLeeKUParkJY. Alpha-lipoic acid increases insulin sensitivity by activating AMPK in skeletal muscle. Biochem Biophys Res Commun.2005;332 (3): 885–91.
32.
HuongDTIdeT. Dietary lipoic acid-dependent changes in the activity and mRNA levels of hepatic lipogenic enzymes in rats. Br J Nutr.2008;100 (1): 79–87.
33.
ParkKGMinAKKohEHKimHSKimMOParkHSKimYDYoonTSJangBKHwangJSKimJBChoiHSParkJYLeeIKLeeKU. Alpha-lipoic acid decreases hepatic lipogenesis through adenosine monophosphate-activated protein kinase (AMPK)-dependent and AMPK-independent pathways. Hepatology.2008;48 (5): 1477–86.
